You are here: Home » Companies » News
Business Standard

Aurobindo Pharma gets USFDA nod for pain treatment injection Acetaminophen

The product will be launched in December 2020

Topics
Aurobindo Pharma | USFDA

Press Trust of India  |  New Delhi 

Aurobindo Pharma wrests second position among drug firms from Lupin
It is a generic version of Mallinckrodt''s Ofirmev injection.

Drug firm on Thursday said it has received final approval from the US health regulator for its generic Acetaminophen injection, used in the treatment of pain in adult and paediatric patients.

The company has received the approval from the US Food & Drug Administration (USFDA) to manufacture and market Acetaminophen injection, 1,000 mg/ 100 mL single-dose vial, said in a BSE filing.

The product will be launched in December 2020, it added.

It is a generic version of Mallinckrodt's Ofirmev injection.

According to IQVIA data, the approved product has an estimated market size of USD 339 million for the twelve months ending August 2020, said.

Acetaminophen Injection is indicated for the treatment of mild to moderate pain in adult and paediatric patients 2 years and older. It is also set to treat moderate to severe pain with adjunctive opioid analgesics in adult and paediatric patients 2 years and older, and reduction of fever, the company noted.

This is the 75th abbreviated new drug application (ANDA) to be approved out of the Unit IV formulation facility in Hyderabad, used for manufacturing injectable and ophthalmic products,it added.

The company now has a total of 449 ANDA approvals (421 final approvals and 28 tentative approvals) from the USFDA, Aurobindo Pharma said.

Shares of Aurobindo Pharma were trading at Rs779.35per scrip on BSE, down 3.22 per cent from its previous close.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, October 22 2020. 13:46 IST
RECOMMENDED FOR YOU
.